STE at a glance
Steris (STE, SEC CIK 1757898) filed its latest 10-K annual report on May 29, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 31, 2026 (FY2026), Steris (STE) reported revenue of $5.9 billion (up 8.7% from FY2025) and net income of $782.3 million. Diluted EPS was $7.93.
- As of June 30, 2026, 40 institutional investment managers tracked by SignalX reported holding Steris (STE) shares worth $9.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sohi Mohsen on August 12, 2026 of 4,058 shares at $235.78 per share.
- In the last 90 days, STE insiders reported 0 open-market purchases ($0) and 1 open-market sale ($957K) on Form 4, a net sale of $957K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $5.9B
- +8.7% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$957K
- 13F holders
- 40 funds
- $9.1B · +3 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $1,492.7M, up 7.3% YoY from $1,391.1M
- Gross margin 45.8% vs 45.1% YoY; operating income $285.8M vs $246.0M
- Best segment Life Sciences revenue $146.7M, up 8.6%; Healthcare largest at $1,048.3M, up 7.6%
- Operating cash flow $367.1M vs $420.0M; free cash flow $279.6M vs $326.5M
- Debt-to-total capital 20.9% vs 21.3%; dividends $0.63/share; planned restructuring charges $55M–$70M through fiscal 2030
Risk Factors
- No material risk-factor changes disclosed; 10-Q refers to March 31, 2026 Form 10-K
- Capital-allocation risk: New $1,000.0 million repurchase authorization replaced prior $500.0 million program
- Share-repurchase liquidity risk: $100.0 million spent, leaving $900.0 million available at June 30, 2026
- Regulatory-compliance risk: No directors or officers adopted, modified, or terminated Rule 10b5-1 arrangements during the quarter
AI summary of the STE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Pierre Boulud appointed to STERIS Board’s Audit Committee effective July 31, 2026
- Appointment expands Boulud’s oversight of financial reporting, controls, and audit matters
Item 5.07: Submission of Matters to a Vote of Security Holders
- 92.25% shareholder participation; quorum confirmed with 89,909,204 shares represented
- All nine director nominees elected for one-year terms; Board reduced to nine members
Item 2.02: Results of Operations and Financial Condition
- Q1 fiscal 2026 results for quarter ended June 30, 2026
- Press release Exhibit 99.1 contains STERIS’s financial results and management commentary
Item 2.05: Costs Associated with Exit or Disposal Activities
- Manufacturing and distribution consolidation into North Carolina Center of Excellence
- Expected pre-tax restructuring charges of $55M–$70M through fiscal 2030
Item EX-99.1: Item EX-99.1
- Q1 FY2027 revenue $1.49B, up 7.3%; constant-currency organic growth 6.2%, indicating broad-based underlying demand
- Adjusted EPS $2.59 versus $2.34; reported diluted EPS $2.04 versus $1.79, despite higher tax rate and tariff costs
AI summaries of STE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STE
Don't miss the next STE filing
- Alerts as it files. A push when STE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STE, by share count.
- Ask anything. An AI agent that reads every STE filing and answers with sources.
STE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Burton Karen L | F | Oct 1, 2026 | 228 | - |
| Sohi Mohsen | M | Aug 12, 2026 | 4,058 | $86.23 |
| Sohi Mohsen | M | Aug 12, 2026 | 4,058 | - |
| Sohi Mohsen | Sell | Aug 12, 2026 | 4,058 | $235.78 |
| Alegria Esther M. | A | Aug 10, 2026 | 512 | - |
| Shah Nirav R | A | Aug 10, 2026 | 1,506 | - |
| Shah Nirav R | A | Aug 10, 2026 | 512 | - |
| Shapiro Louis | A | Aug 10, 2026 | 1,025 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $5.5B | $5.9B |
| Gross Profit | - | $2.4B | $2.6B |
| Operating Income | - | $866.6M | $1.1B |
| Net Income | - | $614.6M | $782.3M |
| Gross Margin | - | 44.0% | 44.2% |
| Op. Margin | - | 15.9% | 18.6% |
| Net Margin | - | 11.3% | 13.2% |
| Balance Sheet | |||
| Total Assets | $11.1B | $10.1B | $10.7B |
| Equity | $6.3B | $6.6B | $7.2B |
| ROE | - | 9.3% | 10.9% |
| Per Share | |||
| EPS | - | $6.20 | $7.93 |
| Cash Flow | |||
| Operating CF | - | $1.1B | $1.3B |
| CapEx | - | $370.1M | $369.0M |
Source: XBRL data in Steris (STE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate STE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 40 | $9.08B |
| Q1 2026 | 37 | $9.54B |
| Q4 2025 | 35 | $10.48B |
| Q3 2025 | 37 | $10.39B |
| Q2 2025 | 34 | $9.63B |
| Q1 2025 | 32 | $6.84B |
| Q4 2024 | 29 | $4.97B |
| Q3 2024 | 25 | $2.47B |
- Goldman Sachs Group+981.6K (+257%)
- D.E. Shaw & Co+333.5K (+189%)
- AQR Capital Management+315.9K (+30%)
- Citadel Advisors LLC+294.4K (+268%)
- Millennium Management+203.8K (+803%)
- Franklin Resources−1.18M (-95%)
- Morgan Stanley−444.2K (-10%)
- Raymond James Financial−426.7K (-41%)
- Two Sigma Investments−422.4K (-88%)
- BlackRock−205.7K (-2%)
- Renaissance Technologies LLC+115.9K
- Blackstone Group+1.9K
- StoneX Group Inc.+1.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 269 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
STE SEC filings: frequently asked questions
Are STE insiders buying or selling?
In the last 90 days, Steris (STE) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $956,795 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold STE stock?
As of June 30, 2026, the largest Steris (STE) holders among the 13F filers tracked by SignalX were BlackRock ($1.9 billion), Vanguard Capital Management LLC ($1.3 billion), State Street Corp ($1.1 billion), Vanguard Portfolio Management LLC ($1.1 billion), Morgan Stanley ($831.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STE's revenue in fiscal year 2026?
For the fiscal year ended March 31, 2026 (FY2026), Steris (STE) reported revenue of $5.9 billion (up 8.7% from FY2025) and net income of $782.3 million. Diluted EPS was $7.93. The figures come from the XBRL data in the 10-K.
What did STE report in its latest 8-K?
Steris (STE) filed an 8-K on August 6, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Pierre Boulud appointed to STERIS Board’s Audit Committee effective July 31, 2026.
What are the latest STE SEC filings?
Steris (STE) filed its latest 10-K annual report on May 29, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 5, 2026.
What is STE's SEC CIK number?
Steris (STE)'s SEC Central Index Key (CIK) is 1757898. EDGAR lists every STE filing under that number.
Ask anything about STE
The research agent reads STE's filings, financials, insider trades and 13F holders, then answers with sources.